4Lebeche D, Kaprielian R, Hajjar R. Modulation of action potential duration on myocyte hypertrophic pathways. J Mol Cell Cardiol, 2006,40(5) : 725-735.
5He ZY, Feng B, Yang SL, et al. Intracardiac basic fibroblast growth factor and transforming growth factorbeta 1 mRNA and their proteins expression level in patients with pressure or volume-overload right or left ventricular hypertrophy. Acta Cardiol, 2005,60 (1) :21- 25.
6Kim N, Kim H, Youm JB,et al. Site specific differential activation of ras/raf/ERK signaling in rabbit isoproterenol-induced left ventricular hypertrophy. Biochim Biophys Acta, 2006,1763 (10) : 1067-1075.
7Wiesel P, Mazzolai L, Nussberger J, et al. Two-kidney, one clip hypertension in mice. Hypertension, 1997, 29 (4) : 1025-1030.
8Thomas WG, Brandenburger Y, Autelitano DJ,et al. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res , 2002,90 (2): 135-142.
9Schultz JE, Witt SA, Nieman ML, et al. Ang Ⅱ and fibroblast growth factor- Mediat espressure-induced hypertrophic response. J Clin Invest, 1999,104 (6) : 709- 719.
10Sumita E. Cultured myocardial cell growth and hypertrophy by Basic fibroblast growth factor. Kokyu To Junkan, 1993,41 (8) : 779-785.
1Li L, Emmett N, Mann D, et al. Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-r~B and transforming growth factor- !8 1/Smad3 in diabetic nephropathy[J]. Exp Biol Med(Maywood), 2010, 235 (3) : 383-391.
